287 related articles for article (PubMed ID: 31444476)
1. TRAIL-based gene delivery and therapeutic strategies.
Zhong HH; Wang HY; Li J; Huang YZ
Acta Pharmacol Sin; 2019 Nov; 40(11):1373-1385. PubMed ID: 31444476
[TBL] [Abstract][Full Text] [Related]
2. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
3. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
4. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA.
Luo C; Miao L; Zhao Y; Musetti S; Wang Y; Shi K; Huang L
Biomaterials; 2016 Sep; 102():239-48. PubMed ID: 27344367
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
6. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
[TBL] [Abstract][Full Text] [Related]
7. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
8. SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy.
Zhou X; Liu Z; Wang H; Liu X; Zhou Z; Tang J; Liu X; Zheng M; Shen Y
J Drug Target; 2019 Mar; 27(3):306-314. PubMed ID: 30188217
[TBL] [Abstract][Full Text] [Related]
9. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment.
Jiang H; Wang S; Zhou X; Wang L; Ye L; Zhou Z; Tang J; Liu X; Teng L; Shen Y
J Control Release; 2018 Sep; 286():254-263. PubMed ID: 30075209
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L; Marzo I; Anel A; Naval J
Biochem Pharmacol; 2012 Jun; 83(11):1475-83. PubMed ID: 22230480
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
Shamimi-Noori S; Yeow WS; Ziauddin MF; Xin H; Tran TL; Xie J; Loehfelm A; Patel P; Yang J; Schrump DS; Fang BL; Nguyen DM
Cancer Gene Ther; 2008 Jun; 15(6):356-70. PubMed ID: 18309355
[TBL] [Abstract][Full Text] [Related]
12. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
14. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
16. [Progress on targeting TRAIL's receptor as antitumor strategy].
Chen SZ
Yao Xue Xue Bao; 2009 Dec; 44(12):1336-42. PubMed ID: 21351465
[TBL] [Abstract][Full Text] [Related]
17. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
[TBL] [Abstract][Full Text] [Related]
18. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
19. Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma.
Wang Y; Li L; Shao N; Hu Z; Chen H; Xu L; Wang C; Cheng Y; Xiao J
Acta Biomater; 2015 Apr; 17():115-24. PubMed ID: 25595474
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
